Reading and Resources

Dietrichs E, et al. Algorithms for the treatment of motor problems in Parkinson’s disease. Acta Neurol Scand. 2017;136:378–385. https://www.ncbi.nlm.nih.gov/pubmed/28133726

Dorsey ER, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68:384-386. https://www.ncbi.nlm.nih.gov/pubmed/17082464

Espay AJ. Management of motor complications in Parkinson disease: current and emerging therapies. Neurol Clin. 2010;28:913-925. https://www.ncbi.nlm.nih.gov/pubmed/17082464

Espay AJ et al. Optimizing extended-release carbidopa/levodopa in Parkinson disease: Consensus on conversion from standard therapy. Neurol Clin Pract. 2017;7:86-93. https://www.ncbi.nlm.nih.gov/pubmed/28243505

Fasano A, et al. Gastrointestinal dysfunction in Parkinson’s disease. Lancet Neurol. 2015;14:625‐639. https://www.ncbi.nlm.nih.gov/pubmed/25987282

Kalia LV, Lang AE. Parkinson’s disease. Lancet. 2015;386:896-912. https://www.ncbi.nlm.nih.gov/pubmed/25904081

Krishnan S, et al. Do nonmotor symptoms in Parkinson’s disease differ from normal aging? Mov Disord. 2011;26:2110-2113. https://www.ncbi.nlm.nih.gov/pubmed/21661056

Marrinan S, et al. Delayed gastric emptying in Parkinson’s disease. Mov Disord. 2014;29:23‐32. https://www.ncbi.nlm.nih.gov/pubmed/24151126

Müller T. Safinamide: an add-on treatment for managing Parkinson’s disease. Clin Pharmacol. 2018;10:31-41. https://www.ncbi.nlm.nih.gov/pubmed/29670409

Nyholm D, et al. Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson’s disease patients. AAPS J. 2013;15:316-323. https://www.ncbi.nlm.nih.gov/pubmed/23229334

Olanow CW, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13:141-149. https://www.ncbi.nlm.nih.gov/pubmed/24361112

Pahwa R, et al. Amantadine extended release for levodopa-induced dyskinesia in Parkinson’s disease (EASED Study). Mov Disord. 2015;30:788-795. https://www.ncbi.nlm.nih.gov/pubmed/25650051

Pedersen SW, et al. Practical Guidance on How to Handle Levodopa/Carbidopa Intestinal Gel Therapy of Advanced PD in a Movement Disorder Clinic. Open Neurol J. 2012;6:37-50. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3406266/

Politis M, et al. Parkinson’s disease symptoms: the patient’s perspective. Mov Disord. 2010;25:1646-1651. https://www.ncbi.nlm.nih.gov/pubmed/20629164